Literature DB >> 16932302

When to discontinue treatment of prolactinoma?

John Ah Wass1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16932302     DOI： 10.1038/ncpendmet0162

Source DB:  PubMed          Journal:  Nat Clin Pract Endocrinol Metab        ISSN： 1745-8366


× No keyword cloud information.
  7 in total

1.  [Female patient with depressive psychosis and visual disturbances].

Authors:  M Neubacher; M Reuter; K Hauenstein
Journal:  Radiologe       Date:  2013-08       Impact factor: 0.635

Review 2.  [Treatment of pituitary gland hyperfunction: from acromegaly to prolactinoma].

Authors:  A Schäffler
Journal:  Internist (Berl)       Date:  2006-12       Impact factor: 0.743

3.  10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.

Authors:  Lukas Andereggen; Janine Frey; Robert H Andres; Marwan El-Koussy; Jürgen Beck; Rolf W Seiler; Emanuel Christ
Journal:  Endocrine       Date:  2016-09-29       Impact factor: 3.633

4.  Impact of primary medical or surgical therapy on prolactinoma patients' BMI and metabolic profile over the long-term.

Authors:  Lukas Andereggen; Janine Frey; Robert H Andres; Markus M Luedi; Jan Gralla; Gerrit A Schubert; Jürgen Beck; Luigi Mariani; Emanuel Christ
Journal:  J Clin Transl Endocrinol       Date:  2021-06-17

5.  Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas.

Authors:  Lukas Andereggen; Janine Frey; Robert H Andres; Markus M Luedi; Hans Rudolf Widmer; Jürgen Beck; Luigi Mariani; Emanuel Christ
Journal:  Sci Rep       Date:  2021-03-04       Impact factor: 4.379

6.  Machine Learning for Outcome Prediction in First-Line Surgery of Prolactinomas.

Authors:  Markus Huber; Markus M Luedi; Gerrit A Schubert; Christian Musahl; Angelo Tortora; Janine Frey; Jürgen Beck; Luigi Mariani; Emanuel Christ; Lukas Andereggen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-16       Impact factor: 5.555

7.  First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center.

Authors:  L Andereggen; J Frey; R H Andres; M M Luedi; M El-Koussy; H R Widmer; J Beck; L Mariani; R W Seiler; E Christ
Journal:  J Endocrinol Invest       Date:  2021-04-13       Impact factor: 4.256
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.